Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006631
Abstract: Key Points One intravenous dose of oncolytic VSV has single-agent activity in patients with relapsed refractory T-cell lymphoma. Direct oncolytic tumor cell killing and subsequent immune cell activation were observed, resulting in durable remissions in… read more here.
Keywords: cell; oncolytic vsv; cell lymphoma; relapsed refractory ... See more keywords